Sorafenib rechallenge in patients with metastatic renal cell carcinoma

BJU International

Volumn 110, Issue 6B, 2012, Pages

  Nozawa, Masahiro ^a   Yamamoto, Yutaka ^a   Minami, Takafumi ^a   Shimizu, Nobutaka ^a   Hatanaka, Yuji ^a   Tsuji, Hidenori ^a   Uemura, Hirotsugu ^a  

^a KINKI UNIVERSITY   (Japan)

Author keywords

rechallenge; renal cell carcinoma; sequential therapy; sorafenib; targeted therapy; tyrosine kinase inhibitor

Indexed keywords

ALPHA INTERFERON; EVEROLIMUS; INTERLEUKIN 2; SORAFENIB; SUNITINIB; THALIDOMIDE;

ADULT; AGED; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CLINICAL ARTICLE; CONFIDENCE INTERVAL; DIARRHEA; DRUG RECHALLENGE; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEART FAILURE; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; KIDNEY METASTASIS; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; NEPHRECTOMY; PANCREAS METASTASIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PYRIDINES; RETREATMENT; RETROSPECTIVE STUDIES;

EID: 84865495976     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10905.x     Document Type: Article

References (32)

1. Hutson TE, Bukowski RM, Cowey CL, Figlin R, Escudier B, Sternberg CN,. Sequential use of targeted agents in the treatment of renal cell carcinoma. Crit Rev Oncol Hematol 2011; 77: 48-62
2. Escudier B, Goupil MG, Massard C, Fizazi K,. Sequential therapy in renal cell carcinoma. Cancer 2009; 115 (Suppl.): 2321-6
3. Porta C, Tortora G, Linassier C, et al,. Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: and expert agreement. Med Oncol 2011; DOI:10.1007/s12032-011-0016-8 (Epub ahead of print)
4. Motzer RJ, Hutson TE, Tomczak P, et al,. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-24 (Pubitemid 46089672)
5. Escudier B, Eisen T, Stadler WM, et al,. Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma. N Engl J Med 2007; 356: 125-34 (Pubitemid 46089673)
6. Sternberg CN, Davis ID, Mardiak J, et al,. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28: 1061-8
7. Hudes G, Carducci M, Tomczak P, et al,. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-81 (Pubitemid 46849157)
8. Motzer RJ, Escudier B, Oudard S, et al,. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo- controlled phase III trial. Lancet 2008; 372: 449-56
9. Tamaskar I, Garcia JA, Elson P, et al,. Antitumor Effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol 2008; 179: 81-6 (Pubitemid 350216728)
10. Zimmermann K, Schmittel A, Steiner U, et al,. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib. Oncology 2009; 76: 350-4
11. Eichelberg C, Heuer R, Chun FK, et al,. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis. Eur Urol 2008; 54: 1373-8
12. Feinberg BA, Jolly P, Wang S-T, et al,. Safety and treatment patterns of angiogenesis inhibitors in patients with metastatic renal cell carcinoma: evidence form US community oncology clinics. Med Oncol 2011; DOI:10.1007/s12032-011-9922-2 (Epub ahead of print)
13. Herrmann E, Marschner N, Grimm MO, et al,. Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma. World J Urol 2011; 29: 361-6
14. Kontovinis L, Lashos K, Karadimou A, et al,. Sequential treatment with sorafenib and sunitinib in metastatic renal cell carcinoma: clinical outcomes from a retrospective clinical study. Med Oncol 2011; DOI:10.1007/s12032-010- 9815-6 (Epub ahead of print)
15. Buchler T, Klapka R, Melichar B, et al,. Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma-data from the Czech registry. Ann Oncol 2011; DOI:10.1093/annonc/mdr065 (Epub ahead of print)
16. Porta C, Procopio G, Carteni G, et al,. Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases. BJU Int 2011; 108: E250-7
17. Choueiri TK, Brick AJ, McDermott D, et al,. Treatment and dosing patterns for angiogenesis inhibitor (AIS) therapies in patients with metastatic renal cell carcinoma (mRCC). Ann Oncol 2008; 19: viii 191 (abstract 593P)
18. Dudek AZ, Zolnierek J, Dham A, Lindgren BR, Szczylik C,. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer 2009; 115: 61-7
19. Sablin MP, Negrier S, Ravaud A, et al,. Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol 2009; 182: 29-34
20. Vickers MM, Choueiri TK, Rogers M, et al,. Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy. Urology 2010; 76: 430-5
21. Zama IN, Hutson TE, Elson P, et al,. Sunitinib rechallenge in metastatic renal cell carcinoma patients. Cancer 2010; 116: 5400-6
22. Chu TF, Rupnick MA, Kerkela R, et al,. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007; 370: 2011-9 (Pubitemid 350236338)
23. Zhu X, Stergiopoulos K, Wu S,. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol 2009; 48: 9-17
24. Motzer RJ, Escudier B, Oudard S, et al,. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010; 116: 4256-65
25. Bellmunt J, Eisen T, Fishman M, Quinn D,. Experience with sorafenib and adverse event management. Crit Rev Oncol Hematol 2011; 78: 24-32
26. Bellmunt J, Eisen T, Szcylik C, Mulders P, Porta C,. A new patient-focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options. BJU Int 2011; 107: 1190-9
27. Hutson TE, Bellmunt J, Porta P, et al,. Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET. Eur J Cancer 2010; 46: 2432-40
28. Eisenhauer EA, Therasse P, Bogaerts J, et al,. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47
29. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M,. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20: 289-96 (Pubitemid 34032623)
30. Motzer RJ, Bacik J, Schwartz LH, et al,. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004; 22: 454-63 (Pubitemid 41079774)
31. Michel MS,. NCT00732914: sequential study to treat renal cell carcinoma. 2010. ClinicalTrials.gov. Available at: http://www.clinicaltrials.gov/ct2/show/ NCT00732914. Accessed August 2011.
32. Escudier B, Szczylik C, Hutson TE, et al,. Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 1280-9